Physician

Adam Shaker Geyer, M.D.

According to 2025 Medicare claims, Adam Geyer, M.D. (NPI: 1508804238) practices dermatology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from New York, NY. This provider's primary affiliated billing organization is ADAM GEYER MD PC (NPI: 1902068414; TIN: 262203325) and primary practice location at 10013-2411.

Geyer's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 510 traditional Medicare patients, billed 43,799 HCPCS/CPT codes, and received $140,947 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 644 prescription claims across 231 beneficiaries totaling $153,270 in drug costs, led by Clobetasol Propionate (Clobetasol Propionate). Open Payments data shows 74 records totaling $1,375. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $57,628 to $140,947. Similarly, Part D prescription costs have moved sharply higher in recent years, from $21,020 to $153,270. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$70K$141K2015 Medicare payment: $57,628 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $59,509 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $58,336 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $71,559 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $92,322 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $92,701 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $120,486 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $120,703 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $127,507 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $140,947 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201518711,531$57,628
201621312,882$59,509
201722911,554$58,336
201826619,066$71,559
201931726,678$92,322
202029632,221$92,701
202138044,459$120,486
202242424,252$120,703
202346537,334$127,507
202451043,799$140,947

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$79K$159K2015 Drug cost: $21,020 (USD; Tot_Drug_Cst)2016 Drug cost: $19,209 (USD; Tot_Drug_Cst)2017 Drug cost: $15,499 (USD; Tot_Drug_Cst)2018 Drug cost: $31,756 (USD; Tot_Drug_Cst)2019 Drug cost: $30,045 (USD; Tot_Drug_Cst)2020 Drug cost: $61,222 (USD; Tot_Drug_Cst)2021 Drug cost: $84,412 (USD; Tot_Drug_Cst)2022 Drug cost: $139,960 (USD; Tot_Drug_Cst)2023 Drug cost: $158,843 (USD; Tot_Drug_Cst)2024 Drug cost: $153,270 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201596233$21,020
201689215$19,209
201795204$15,499
2018132300$31,756
2019122277$30,045
2020168422$61,222
2021172404$84,412
2022176424$139,960
2023216504$158,843
2024231644$153,270

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths134154$89
11102Biopsy of related skin growth, first growth118141$74
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more372500$67
17000Destruction of precancer skin growth, 1 growth244311$43
17003Destruction of precancer skin growth, 2-14 growths167783$6

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Clobetasol PropionateClobetasol Propionate411,102$2,456
FluorouracilFluorouracil30990$1,856
CiclopiroxCiclopirox Olamine672,250$1,523
MetronidazoleMetronidazole25780$1,490
Clindamycin PhosphateClindamycin Phosphate451,305$1,045

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.74$1,375ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Adam Shaker Geyer, M.D.?

Tedicare shows public-source Medicare data for Adam Shaker Geyer, M.D. (NPI 1508804238), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Shaker Geyer, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adam Shaker Geyer, M.D.?

Adam Shaker Geyer, M.D. is linked to ADAM GEYER MD PC (billing NPI 1902068414) in the available physician profile data.

Does Adam Shaker Geyer, M.D. have Open Payments data?

Adam Shaker Geyer, M.D. has 74 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.